ANN ARBOR—The pharmaceutical firm Esperion Therapeutics Inc. feported a rise in sales of its novel cholesterol-reducing drugs in the second quarter ended June 30 but still posted a loss as efforts to boost the drug’s sales continue. The company posted a loss of $43.7 million or $1.67 a share in the quarter, compared to net
ANN ARBOR—Esperion Therapeutics Inc. announced the appointment of Sheldon Koenig as president, CEO, and board member, effective immediately. He succeeds Tim Mayleben, whom company officials said “decided to step down” after a decade as the company’s CEO. Mayleben will continue to serve as a senior advisor “to help ensure a smooth transition,” company officials said
ANN ARBOR—Esperion Therapeutics, developers of a novel class of cholesterol-reducing drugs, announced that an investor group led by New York City-based Oberland Capital Management LLC agreed to provide the third and final tranche of funding under the revenue-based funding agreement totaling $50 million. The remaining funds are being released sooner than expected and in parallel
ANN ARBOR—Esperion Therapeutics Inc. reported a loss of $85.4 million or $3.07 a share in the third quarter of 2020, vs. a loss of $68.4 million or $2.52 a share in the same quarter of 2019. Revenue was $3.8 million, including $3.3 million in product sales and $500,000 in partner reimbursement. Revenue a year earlier
ANN ARBOR—Esperion Therapeutics Inc. has finally launched the cholesterol busting drug the company has been development and made Nexlizet tablets available in the United States. Nexlizet is a combination of bempedoic acid and ezetimibe. Bempedoic acid is the Esperion-developed active ingredient in Nexletol tablets, approved by the U.S. Food and Drug Administration and introduced earlier
ANN ARBOR—After years of development, Nexletol, the new cholesterol-reducer from Ann Arbor’s Esperion Therapeutics Inc., is now on the market and available in pharmacies in the United States. Nexletol uses a new mechanism of action to reduce low-density lipoprotein (LDL-C), the so-called bad cholesterol in the bloodstream, the cholesterol that can cause arterial blockages that
ANN ARBOR—Cholesterol-lowering drug developer Esperino Therapeutics Inc. has appointed Alan Fuhrman as a Class III director, with a term expiring at the 2022 meeting of stockholders. “On behalf of the Lipid Management team and our directors, I am very pleased to welcome Alan to the Esperion board. His extensive financial leadership experience will be extremely
ANN ARBOR—Esperion Therapeutics Inc. announced U.S. Food and Drug Administration approval of Nexlizet, a combination tablet of Esperion’s new non-staticholesterol reducing drug bempedoic acid and an earlier non-statin cholesterol-reducer, exetimibe. The new drug will be an oral, once-daily, non-statin medicine designed to reduce levels of LDL cholesterol, the so-called bad cholesterol, intended for people who
ANN ARBOR—Esperion Therapeutics Inc. has announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has issued a “positive opinion” for both its bempedoic acid and its benpedoic acid-ezetimibe tablets to treat high cholesterol and other risky conditions involving lipids in the bloodstream. Company officials said the committee “found there were no
ANN ARBOR—Esperion Therapeutics Inc., a developer of a new class of cholesterol-reducing drugs, announced that the compensation committee of its board of directors granted non-qualified stock options to purchase an aggregate of 39,500 shares of its common stock and 35,388 restricted stock units (RSUs) to 18 new employees under Esperion’s 2017 Inducement Equity Incentive Plan.
